

Lundbeck's scientific presentations at AES 2025

Bexicaserin for the Treatment of Seizures in Developmental and Epileptic Encephalopathies: Interim Analysis of an Expanded Access Program for Participants on Treatment for up to 2 Years ⁴	Poster presentation:Caitlin Sylvia	Saturday, Dec 6
Analyses of Bexicaserin for the Treatment of Seizures in Developmental and Epileptic Encephalopathies: Response Over Time and Responder Rates in the Phase 1b/2a PACIFIC Trial Open-Label Extension ¹	Poster presentation:David G. Vossler, MD	Saturday, Dec 6
Patterns of Antiseizure Medication Utilization in Participants with Developmental and Epileptic Encephalopathies and Responses to Bexicaserin Treatment in the Phase 1b/2a PACIFIC Trial ⁵	Poster presentation:Pavel Klein, MD	Saturday, Dec 6
Bexicaserin Has Negligible Drug–Drug Interaction Potential When Co-Administered With Anti-Seizure Medications That Are Inhibitors or Inducers of CYP/UGT Enzymes ⁶	Poster presentation:Nuggehally R. Srinivas	Sunday, Dec 7
Bexicaserin Selectively Activates 5-HT _{2C} Receptors to Modulate Activity in the Thalamocortical Circuit Relevant for Absence Seizures ⁷	Poster presentation:Jesper Frank Bastlund	Sunday, Dec 7
An Ethnobridging Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Bexicaserin ⁸	Poster presentation:Rosa Chan	Monday, Dec 8
Lack of Potential for Bexicaserin to Prolong QT Interval at Supratherapeutic Doses ⁹	Poster presentation:Jonathan Williams	Monday, Dec 8
Effects of Bexicaserin on Neural Circuits in the DBA/1 Mouse Model of Sudden Unexpected Death in Epilepsy (SUDEP) ¹⁰	Poster presentation:Sheryl Vermudez	Monday, Dec 8